BR112012008019A2 - derivados de purina úteis como inibidores de hsp90 - Google Patents

derivados de purina úteis como inibidores de hsp90

Info

Publication number
BR112012008019A2
BR112012008019A2 BR112012008019A BR112012008019A BR112012008019A2 BR 112012008019 A2 BR112012008019 A2 BR 112012008019A2 BR 112012008019 A BR112012008019 A BR 112012008019A BR 112012008019 A BR112012008019 A BR 112012008019A BR 112012008019 A2 BR112012008019 A2 BR 112012008019A2
Authority
BR
Brazil
Prior art keywords
hsp90 inhibitors
purine derivatives
derivatives useful
useful
compounds
Prior art date
Application number
BR112012008019A
Other languages
English (en)
Inventor
Gabriela Chiosis
Tony Taldone
Weilin Sun
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of BR112012008019A2 publication Critical patent/BR112012008019A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

derivados de purina úteis como inibidores de hsp90. a presente invenção proporciona derivados de purina substituída e compostos relacionados das fórmulas mostradas. esses compostos são úteis como inibidores de hsp90, e, portanto, no tratamento de doenças relacionadas. (fórmulas) z~ 1~ - z~ 3~, x~ a~ - x~ c~, x~ 2~, x~ 4~, y e r são conforme definidos no relatório descritivo.
BR112012008019A 2009-10-07 2010-10-07 derivados de purina úteis como inibidores de hsp90 BR112012008019A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24934909P 2009-10-07 2009-10-07
PCT/US2010/051872 WO2011044394A1 (en) 2009-10-07 2010-10-07 Purine derivatives useful as hsp90 inhibitors

Publications (1)

Publication Number Publication Date
BR112012008019A2 true BR112012008019A2 (pt) 2016-03-01

Family

ID=43857159

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008019A BR112012008019A2 (pt) 2009-10-07 2010-10-07 derivados de purina úteis como inibidores de hsp90

Country Status (16)

Country Link
US (2) US9328114B2 (pt)
EP (2) EP3091019B1 (pt)
JP (3) JP5941407B2 (pt)
KR (2) KR101906568B1 (pt)
CN (3) CN106083855B (pt)
AU (1) AU2010303343B2 (pt)
BR (1) BR112012008019A2 (pt)
CA (1) CA2776308C (pt)
DK (1) DK2486039T3 (pt)
EA (1) EA029272B1 (pt)
ES (2) ES2589403T3 (pt)
LT (1) LT2486039T (pt)
MX (1) MX340714B (pt)
NZ (2) NZ625593A (pt)
PT (1) PT2486039T (pt)
WO (1) WO2011044394A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
EP3305297A1 (en) * 2006-06-30 2018-04-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
MX340714B (es) 2009-10-07 2016-07-22 Sloan-Kettering Inst For Cancer Res * Inhibidores de hsp90.
AU2012240079B2 (en) 2011-04-05 2017-05-18 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EP2694505B1 (en) 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
AU2012282903A1 (en) 2011-07-08 2014-02-13 Sloan-Kettering Institute For Cancer Research Uses of labeled HSP90 inhibitors
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
CN105899503B (zh) 2013-08-16 2020-08-18 纪念斯隆-凯特琳癌症中心 选择性grp94抑制剂和其用途
CA2921410C (en) 2013-08-23 2023-03-28 Neupharma, Inc. Quinazoline derivatives, compositions and their use as kinase inhibitors
WO2015138039A1 (en) 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
EA201790444A1 (ru) 2014-09-17 2017-08-31 Мемориал Слоун Кеттеринг Кэнсэ Сентр Hsp90-направленная визуализация и терапия воспаления и инфекции
TW201722422A (zh) 2015-10-05 2017-07-01 美國紀念斯隆-凱特琳癌症中心 用於治療癌症之合理組合療法
US10544106B2 (en) * 2016-08-15 2020-01-28 Neupharma, Inc. Certain chemical entities, compositions, and methods
IL296355A (en) * 2017-04-24 2022-11-01 Samus Therapeutics Inc Hsp90 inhibitor oral formulations and related methods
US20210161902A1 (en) * 2017-06-23 2021-06-03 Samus Therapeutics, Inc. Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE460423T1 (de) 1997-05-14 2010-03-15 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
CA2370007A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
AU2002228771B2 (en) 2000-11-02 2007-10-25 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to HSP90
CA2464031A1 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
NL1019258C2 (nl) * 2001-10-30 2003-05-02 Iku Holding Montfoort Bv Bevestigingsconstructie, in het bijzonder voor een buitenspiegel van een motorvoertuig.
AU2002356922A1 (en) 2001-11-09 2003-05-26 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
BR0308056A (pt) 2002-02-28 2004-12-07 Astrazeneca Ab Composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
US7592143B2 (en) 2003-04-18 2009-09-22 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
MXPA06002997A (es) 2003-09-18 2007-02-08 Conforma Therapeutics Corp Novedosos compuestos heterociclicos como inhibidores- hsp90.
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
JP4870762B2 (ja) 2005-07-27 2012-02-08 クゥアルコム・インコーポレイテッド Ｆｏｒｗａｒｄｌｉｎｋｏｎｌｙ物理層のためのシステムおよび方法
JP2009536960A (ja) * 2006-05-12 2009-10-22 ミリアド ジェネティクス， インコーポレイテッド 治療用化合物および癌におけるそれらの使用
WO2007143630A2 (en) 2006-06-02 2007-12-13 Nexgenix Pharmaceuticals Treatment of neurofibromatosis with hsp90 inhibitors
EP3305297A1 (en) * 2006-06-30 2018-04-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
US20080053862A1 (en) 2006-06-30 2008-03-06 Sanford, L.P. Interlocking Nestable Article Holder
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
US20080234297A1 (en) 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
ES2430217T3 (es) 2007-03-20 2013-11-19 Curis, Inc. Aminopiridina condensada como inhibidores de HSP90
EP2183221A1 (en) 2007-07-12 2010-05-12 Crystax Pharmaceuticals S.L. New compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CN101909440A (zh) * 2007-11-14 2010-12-08 瑞科西有限公司 治疗用化合物及其在治疗疾病和障碍中的用途
MX340714B (es) 2009-10-07 2016-07-22 Sloan-Kettering Inst For Cancer Res * Inhibidores de hsp90.
AU2012240079B2 (en) 2011-04-05 2017-05-18 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EP2694505B1 (en) 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
CN105899503B (zh) 2013-08-16 2020-08-18 纪念斯隆-凯特琳癌症中心 选择性grp94抑制剂和其用途

Also Published As

Publication number Publication date
PT2486039T (pt) 2016-09-06
EP2486039B1 (en) 2016-06-01
EP2486039A4 (en) 2012-08-15
JP2018104451A (ja) 2018-07-05
CN106083855A (zh) 2016-11-09
EA201270535A1 (ru) 2012-09-28
JP5941407B2 (ja) 2016-06-29
EP3091019A2 (en) 2016-11-09
JP2016145262A (ja) 2016-08-12
KR20180112117A (ko) 2018-10-11
EP3091019A3 (en) 2017-01-18
EP3091019B1 (en) 2019-04-03
ES2733131T3 (es) 2019-11-27
US20120208806A1 (en) 2012-08-16
LT2486039T (lt) 2016-10-10
DK2486039T3 (en) 2016-09-12
MX340714B (es) 2016-07-22
JP2013507381A (ja) 2013-03-04
NZ625593A (en) 2016-03-31
CN105924443A (zh) 2016-09-07
CN106083855B (zh) 2020-04-10
EA029272B1 (ru) 2018-03-30
AU2010303343A1 (en) 2012-04-19
ES2589403T3 (es) 2016-11-14
KR20120083898A (ko) 2012-07-26
US20160310497A1 (en) 2016-10-27
JP6326088B2 (ja) 2018-05-16
CA2776308C (en) 2020-01-28
KR102129420B1 (ko) 2020-07-03
AU2010303343B2 (en) 2015-11-19
US10172863B2 (en) 2019-01-08
MX2012004089A (es) 2012-08-23
US9328114B2 (en) 2016-05-03
CA2776308A1 (en) 2011-04-14
NZ599138A (en) 2014-06-27
JP6804483B2 (ja) 2020-12-23
WO2011044394A1 (en) 2011-04-14
KR101906568B1 (ko) 2018-10-10
EP2486039A1 (en) 2012-08-15
CN102639534A (zh) 2012-08-15

Similar Documents

Publication Publication Date Title
BR112012008019A2 (pt) derivados de purina úteis como inibidores de hsp90
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
MA32811B1 (fr) Nouveaux composés
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
UY29826A1 (es) Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones
SG10201804835VA (en) Substituted nucleosides, nucleotides and analogs thereof
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
MA32505B1 (fr) 5-alcynyl-pyrimidines
MY150518A (en) Substituted gamma lactams as therapeutic agents
UY32125A (es) Compuestos novedosos como ligandos de receptores de canabinoides
BR112012029647A2 (pt) novos derivados de pirimidinas
AP2011005978A0 (en) 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.
UA112795C2 (uk) Біциклічні піразинонові похідні
PH12015501088A1 (en) Dimeric compounds
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
ECSP11010816A (es) Nuevos Compuestos
MX2010009837A (es) Tiazolil-dihidro-indazoles.
WO2010012745A3 (en) Benzimidazoles
TN2011000531A1 (en) 5- alkynyl - pyridines
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
UY32447A (es) Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2599 DE 27-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]